An observational study in Intracranial Aneurysm and Flow Diverter, sponsored by Acandis GmbH. Recruiting at 17 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-04.
Sponsored by Acandis GmbH · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Intracranial Aneurysm with a site in Germany — 9 open to participants now, 14 under way, none of them phase 3. Intracranial Aneurysm · Germany.
Among the 46 studies in Intracranial Aneurysm with a site in Germany, this one is the 20th largest by planned enrollment of the 32 observational ones that give a count, is one of 2 that started in 2022, is one of 33 observational ones, reaches primary completion later than 4 of the 13 other live ones, and was the 42nd registered.
419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.
Browse Intracranial Aneurysm studies →9 of the 46 studies in Intracranial Aneurysm with a site in Germany are open now. Recruiting first, the newest first:
Phenox GmbH · Sites in Germany, France, Italy and 2 more countries
Mizuho Corporation · Sites in Germany
Ages 18+
LuSeed Vascular LTD. · Sites in Germany, Bulgaria, Israel and 1 more country
Ages 18–80
Balt Extrusion · Sites in Germany, France, Spain
Ages 2+
Medical University of South Carolina · Sites in Germany, United States, Canada and 6 more countries
Ages 1–120
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 158 is below the median of 200 across 191 observational studies indexed under Intracranial Aneurysm.
Median enrollment 38 across the 13 interventional studies, 206 across the 32 observational. Of the 22 that completed or were terminated, 6 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 46 have an industry lead sponsor. The 10 most frequent:
Acandis GmbH is the lead sponsor of 11 studies on the registry; 7 are open to participants now.
Acandis GmbH has 3 studies filed under Intracranial Aneurysm — fewer than ten, so there is no comparison to draw.
2 of the studies in Intracranial Aneurysm with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06761365LuSeed Vascular LTD.LUMENS-1 EU EFS CIP | 2026-12 |
| NCT06798740Mizuho CorporationPost Market Registry Study of Intracranial Aneurysms Treated With Sugita Clipping Devices | 2027-02-14 |
Add all 2 to your calendar (.ics) → With an account.
Among the 46 studies in Intracranial Aneurysm with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To analyse the clinical safety and efficacy of the DERIVO® 2heal® Embolisation Device in the standard clinical routine of flow diversion treatment with respect to the mid- and long-term clinical and angiographic outcomes.
The purpose of the DERIVO® 2heal® trial is to conduct a post market clinical follow-up (PMCF) study of the use of the DERIVO® 2heal® Embolisation Device in clinical practice according to EU MDCGs guidance. The DERIVO® 2heal® Study is designed as a prospective, single-arm, multicenter, open-label, national study conducted in Germany with approximately 15 sites planned. The study aims to investigate potential residual risks associated with the use of the device and to update the clinical evaluation of the device in order to ensure the long-term safety and performance of the DERIVO® 2heal® Embolisation Device after its placing on the market. For this purpose, the DERIVO® 2heal® Study will systematically collect information on technical success, safety, and clinical success of treatment of intracranial aneurysms with DERIVO® 2heal® Embolisation Device in clinical practice.
The study duration is expected to be 36 months of enrolment and 12 months follow-up of patients. Up to 158 patients should be enroled at approx. 15 study sites in Germany.
Informed consent will be obtained from all patients prior to implantation of the DERIVO® 2heal® Embolisation Device. In exceptional cases, informed consent may be obtained after the intervention, as the study is purely data collection. It should be noted that the signed informed consent form must be obtained before recording of data in the study and prior any study-specific assessments. Informed consent process will be performed according to ICH-GCP standards. In case of emergency situations when the treatment needs to be performed immediately and informed consent cannot be given prior to the rescue treatment, the informed consent can be obtained retrospectively from the patient or patient's legal representative.
The analysis population will be consist of all patients enrolled who were treated with DERIVO® 2heal® Embolisation device or in whom an attempt of DERIVO® 2heal® Embolisation device implantation was made.
Personal data will be processed in accordance with the relevant national and international legislation and good clinical practice. Data will only be processed for the purpose of the PMCF study. Person-identifiable data will not leave the unit from which they originated, and for pseudonymized data, keys to identification numbers will be held confidentially by the responsible person. Individual patient's medical information will be recorded in the study only in pseudonymized form.
All data in this project are captured in eCRFs and stored into an electronic clinical database. Quality control and data validation procedures such as programmed automatic edit and consistency checks ensure data validity and accuracy immediately at the point of entry into this database. The database application which is used to capture electronic clinical trial data is protected from unauthorized access it is, among other features, access restricted, contains rights and roles functionalities, provides electronic authentication of data entries, maintains an electronic audit trail and provides appropriate data backup functionalities.
After data entry, study monitoring team will perform source data verification and issue monitoring queries directly in the database application.
The database will only be locked after all queries and discrepancies that may have occurred during data entry have been resolved. After database lock, data will be exported in an electronic format and transferred to the responsible biometrician for analysis. The locked database may also be used to generate subject listings and tabulations.
The results of the trial will be reported to the central Ethics Committees after the study was completed. By signing the protocol, the investigator agrees that the results of the clinical investigation may be used for publication. The investigator also agrees that is not permitted to publish any data related to the trial independent of the Sponsor.
All patients who were selected for flow diversion therapy and will be treated with DERIVO® 2heal® Embolisation Device due to intracranial aneurysm according to clinical routine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Flow diversion therapy fpr intracranial aneurysm treatment.
Primary efficacy endpoint
• Rate of complete aneurysm occlusion
Time frame: 6 weeks +/- 3weeks; 6months +/- 3 months; 12months +/-3months
Primary safety endpoint
* Stroke/Death Occurrence Percentage of subjects with major stroke in the territory of treated artery or neurological death post-procedure * Rate of device-related \& procedure-related complications (e.g. ICH, in-stent stenosis, in-stent thrombosis)
Time frame: 12month ± 3month
Primary clinical endpoint
• Good Clinical outcome
Time frame: 6 weeks ± 3weeks; 6months ± 3 months; 12months ± 3months
Secondary efficacy endpoint
* Wall apposition of the flow-diverter(s) per patient as determined by the treating physician and the core-lab after treatment. 1. Correct wall apposition in the parent vessel 2. Gap between FD and vessel wall \< 25 % of vessel diameter 3. Gap between FD and vessel wall \>25 % of vessel diameter * Stasis / flow changes in the aneurysm (O´Kelly Marotta Scale/Kamran grading scale)
Time frame: Measured directly after treatment
Secondary safety endpoint
• Rate of participants (%) with significant parent artery stenosis (\> 50%) or retreatment of the target aneurysm post-procedure
Time frame: 12months ± 3months
Started Dec 2022 (actual). Primary completion is estimated for Dec 2025, 36 months after the start.
Of 105 observational studies under Intracranial Aneurysm, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 145. This study's planned 36 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acandis GmbH